Protara Therapeutics, Inc.

NasdaqGM:TARA Stock Report

Market Cap: US$123.1m

Protara Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:TARA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
14 May 25BuyUS$63,800Richard LevyIndividual20,000US$3.19
12 Sep 24SellUS$271,715Opaleye Management Inc.Company158,901US$1.71
10 Sep 24SellUS$114,251Opaleye Management Inc.Company61,992US$1.89
16 Jul 24SellUS$27,828Opaleye Management Inc.Company11,396US$2.44
11 Jul 24SellUS$175,842Opaleye Management Inc.Company74,551US$2.40
01 Jul 24SellUS$17,598Opaleye Management Inc.Company8,288US$2.12
28 Jun 24SellUS$142,503Opaleye Management Inc.Company64,568US$2.26
25 Jun 24SellUS$28,734Opaleye Management Inc.Company12,725US$2.26
31 May 24SellUS$44,008Opaleye Management Inc.Company15,054US$2.94
22 May 24SellUS$130,434Opaleye Management Inc.Company42,800US$3.06

Insider Trading Volume

Insider Buying: TARA insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of TARA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders979,5122.66%
VC/PE Firms3,400,0009.25%
General Public4,718,68012.8%
Institutions27,669,27375.3%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 87.4%.

Top Shareholders

Top 25 shareholders own 79.68% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.3%
Janus Henderson Group plc
3,788,176US$12.7m66.8%no data
9.25%
RA Capital Management, L.P.
3,400,000US$11.4m79%0.17%
5.68%
Toronto-Dominion Bank, Securities Investments
2,088,937US$7.0m0%0.09%
4.71%
Opaleye Management Inc.
1,730,000US$5.8m-5.21%1.11%
4.57%
Blackstone Alternative Asset Management L.P.
1,680,000US$5.6m0%1.0%
4.36%
The Vanguard Group, Inc.
1,602,852US$5.4m17.9%no data
4.29%
Velan Capital Partners LP
1,579,000US$5.3m175%6.55%
3.91%
Sio Capital Management, LLC
1,437,500US$4.8m0%1.63%
3.81%
Integral Health Asset Management, LLC
1,400,000US$4.7m0%0.43%
3.48%
Acorn Bioventures
1,279,800US$4.3m0%3.05%
2.96%
Catalio Capital Management, LP
1,088,691US$3.6m0%0.84%
2.79%
Citadel Advisors LLC
1,027,534US$3.4m51%no data
2.33%
Jesse Shefferman
857,122US$2.9m3.49%no data
2.32%
Woodline Partners LP
853,160US$2.9m0.19%0.02%
2.18%
5AM Venture Management, LLC
800,000US$2.7m0%0.97%
1.73%
UBS Asset Management AG
636,674US$2.1m326%no data
1.71%
BlackRock, Inc.
630,459US$2.1m443%no data
1.63%
Heights Capital Management, Inc.
600,380US$2.0m0%no data
1.46%
Baker Bros. Advisors LP
536,832US$1.8m0%0.01%
1.41%
Driehaus Capital Management LLC
517,152US$1.7m0%0.01%
1.01%
Millennium Management LLC
371,453US$1.2m2,480%no data
0.98%
Superstring Capital Management LP
360,000US$1.2m0%1.28%
0.95%
Ikarian Capital, LLC
350,489US$1.2m125%0.43%
0.94%
Geode Capital Management, LLC
346,697US$1.2m93.1%no data
0.9%
StemPoint Capital LP
332,394US$1.1m-64.8%0.34%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/17 21:42
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Protara Therapeutics, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Li Wang WatsekCantor Fitzgerald & Co.
Andrew FeinH.C. Wainwright & Co.
Leland GershellOppenheimer & Co. Inc.